Family-owned Italian drugmaker Recordati SpA is exploring strategic options that may lead to a sale amid potential interest from Asian buyers, according to people with knowledge of the matter.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
